– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation –
– Phase 1b data from ABI-1179 accepted for late-breaker poster presentation –
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for ABI-5366 and ABI-1179, herpes simplex virus (HSV) helicase-primase inhibitor candidates, will be featured in multiple presentations, including one late-breaker, at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) taking place April 17-21, 2026, in Munich, Germany.
“The selection of ABI-5366 for oral presentation at ESCMID underscores the strength and clinical relevance of the data generated to date, including additional results from the monthly dosing cohort,” said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. “We are also pleased to see the first scientific presentation of Phase 1b data for ABI-1179 recognized as a late-breaker presentation, which highlight its potential as a long-acting therapeutic option for patients with recurrent genital herpes.”
Details of the presentations are as follows:
ABI-5366:
- Oral Presentation: ABI-5366-101: a phase 1b study of a novel, oral, long-acting, investigational HSV helicase-primase inhibitor in recurrent genital herpes
Presenter: Mark Bloch, MBBS, Momentum Clinical Research and Kirby Institute, University of New South Wales
Session Date and Time: April 20, 2026, at 5:30 PM CEST - Poster Presentation: Virologic analyses following treatment with ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor in participants seropositive for HSV-2 with recurrent genital herpes
Presenter: Kathryn Kitrinos, PhD, Assembly Bio
Session Date and Time: April 18, 2026, at 12:00 PM CEST - Poster Presentation: The safety and tolerability of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor in participants with recurrent genital herpes
Presenter: Cory Sellwood, MBBS, New Zealand Clinical Research
Session Date and Time: April 18, 2026, at 12:00 PM CEST
ABI-1179:
- Poster Presentation (Late-Breaker): The safety and efficacy of ABI-1179, a novel, oral, long-acting HSV helicase-primase inhibitor for recurrent genital herpes: interim results from a phase 1b study
Presenter: Mark Bloch, MBBS, Momentum Clinical Research and Kirby Institute, University of New South Wales
Session Date and Time: April 21, 2026, at 12:00 PM CEST
Assembly Bio intends to make the posters available on the “Events & Presentations” page in the “Investors” section and on the “Publications” page in the “Pipeline” section of its website at www.assemblybio.com.
ABI-5366 and ABI-1179 are investigational product candidates that have not been approved anywhere globally, and their safety and efficacy have not been established. They are exclusively licensed to Gilead Sciences, Inc. (Gilead) under the collaboration between Assembly Bio and Gilead, and Gilead has the sole right and responsibility for further clinical development and commercialization of these programs.
